Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Veracyte (VCYT)

Veracyte expects 2025 revenue of $515 million to $517 million, up about 16%

Positive Impact 3 of 5 earnings Written later

Veracyte preliminarily estimated full-year 2025 total revenue of $515 million to $517 million, up about 16%, and fourth-quarter revenue of $138 million to $140 million. The figures are unaudited and may change when audited results are released, expected in February 2026. The company also initiated 2026 total revenue guidance of $570 million to $582 million, or 10% to 13% growth.

Key points

  • Full-year 2025 testing volume of approximately 169,700 tests, up 19%
  • Fourth-quarter 2025 total revenue of $138 million to $140 million, up 16% to 18% from a year earlier
  • 2026 guidance: total revenue of $570 million to $582 million and adjusted EBITDA margin of 25%
  • Audited full-year 2025 results to be reported on an earnings call in February 2026

The filing

CompanyVeracyte (VCYT)
Form8-K, current report
Filed with the SECJan 12, 2026, 6:05 AM ET
Accession number0001384101-26-000002

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:54 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 12, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.